Table 2.

Cox regressions for overall survival in AIDS-related DLBCL.

Characteristic	Training (n = 90)				Validation (n = 63)
	Univariate		Multivariate		Univariate		Multivariate
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Male sex	1.122 (0.550–2.290)	0.752			1.271 (0.499–3.237)	0.615
Age > 60 years	2.961 (1.621–5.409)	0.001	2.873 (1.522–5.421)	0.001	1.940 (1.005–3.745)	0.048	1.614 (0.801–3.254)	0.181
LDH > ULN	3.052 (1.378–6.758)	0.006	2.421 (1.058–5.537)	0.036	1.810 (0.835–3.924)	0.133	1.395 (0.617–3.155)	0.424
ECOG PS > 1	1.414 (0.832–2.402)	0.200	1.502 (0.870–2.594)	0.144	1.598 (0.868–2.940)	0.132	1.303 (0.641–2.652)	0.465
Ann Arbor stage III/IV	1.072 (0.634–1.812)	0.795	1.196 (0.608–2.352)	0.604	1.618 (0.871–3.005)	0.128	1.418 (0.620–3.243)	0.408
Extranodal sites > 1	0.992 (0.549–1.795)	0.980	0.781 (0.366–1.666)	0.522	1.250 (0.664–2.354)	0.489	0.664 (0.277–1.593)	0.359
Hb/RDW ratio < 8.5	1.936 (1.134–3.304)	0.016	1.897 (1.094–3.290)	0.023	3.219 (1.596–6.494)	0.001	2.645 (1.267–5.522)	0.010
B symptoms (Yes)	1.671 (0.880–3.173)	0.117			1.652 (0.731–3.730)	0.227
Bulky disease (Yes)	1.538 (0.907–2.608)	0.110			3.197 (1.725–5.926)	0.001
Prior history of HIV (Yes)	0.902 (0.505–1.613)	0.728			1.340 (0.658–2.728)	0.420
cART at baseline (Yes)	1.364 (0.630–2.956)	0.431			0.719 (0.292–1.773)	0.474
CD4 count < 200, cells/μL	1.896 (1.078–3.328)	0.026			1.468 (0.779–2.768)	0.235
CD4/CD8 < 0.41	2.158 (1.137–4.097)	0.019	2.151 (1.076–4.301)	0.030	1.729 (0.799–3.742)	0.165	1.543 (0.678–3.511)	0.302

DLBCL, diffuse large B-cell lymphoma; HR, hazard ratio; CI, confidence interval; LDH, lactate dehydrogenase; ULN, upper limit of normal; ECOG PS, Eastern Cooperative Oncology Group performance status; Hb/RDW ratio, ratio of hemoglobin (g/dL) to red cell distribution width (%); cART, combined antiretroviral therapy.

The bold means P < 0.05.